$4.34
1.14% day before yesterday
Nasdaq, May 30, 10:00 pm CET
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Vanda Pharmaceuticals Inc. Stock price

$4.34
-0.17 3.77% 1M
-0.70 13.89% 6M
-0.45 9.39% YTD
-0.67 13.37% 1Y
-5.88 57.53% 3Y
-7.56 63.53% 5Y
-5.86 57.45% 10Y
Nasdaq, Closing price Fri, May 30 2025
-0.05 1.14%
ISIN
US9216591084
Symbol
VNDA
Sector
Industry

Key metrics

Market capitalization $255.78m
Enterprise Value $-80.25m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.40
EV/Sales (TTM) EV/Sales -0.40
P/S ratio (TTM) P/S ratio 1.27
P/B ratio (TTM) P/B ratio 0.50
Revenue growth (TTM) Revenue growth 13.37%
Revenue (TTM) Revenue $201.35m
EBIT (operating result TTM) EBIT $-72.45m
Free Cash Flow (TTM) Free Cash Flow $-57.39m
Cash position $340.91m
EPS (TTM) EPS $-0.76
P/E forward negative
P/S forward 1.12
EV/Sales forward negative
Short interest 8.57%
Show more

Is Vanda Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.

Vanda Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Vanda Pharmaceuticals Inc. forecast:

Buy
67%
Hold
33%

Financial data from Vanda Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
201 201
13% 13%
100%
- Direct Costs 11 11
15% 15%
6%
190 190
16% 16%
94%
- Selling and Administrative Expenses 166 166
56% 56%
83%
- Research and Development Expense 89 89
13% 13%
44%
-65 -65
205% 205%
-33%
- Depreciation and Amortization 7.01 7.01
88% 88%
3%
EBIT (Operating Income) EBIT -72 -72
188% 188%
-36%
Net Profit -44 -44
805% 805%
-22%

In millions USD.

Don't miss a Thing! We will send you all news about Vanda Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vanda Pharmaceuticals Inc. Stock News

Neutral
PRNewsWire
5 days ago
WASHINGTON , May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held in Scottsdale, Arizona, from May 27 through May 30, 2025. The following will be presented: May 27, 2025 Presentation Title: "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioe...
Neutral
PRNewsWire
16 days ago
WASHINGTON , May 16, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in investor meetings at the Mizuho Neuro & Ophthalmology Summit 2025 in New York City on Wednesday, May 21, 2025. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of inno...
Neutral
Seeking Alpha
25 days ago
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q1 2025 Results Conference Call May 7, 2025 4:30 PM ET Company Participants Kevin Moran - CFO Mihael Polymeropoulos - President, Chairman and CEO Tim Williams - Senior Vice President and General Counsel Conference Call Participants Andrew Tsai - Jefferies Charles Duncan - Cantor Fitzgerald Operator Good afternoon, and welcome to the Quarter One 2025 Van...
More Vanda Pharmaceuticals Inc. News

Company Profile

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Head office United States
CEO Mihael Polymeropoulos
Employees 368
Founded 2002
Website www.vandapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today